TerminatedPhase 2NCT03154333
Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)
Studying Epidermolysis bullosa simplex
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Castle Creek Pharmaceuticals, LLC
- Principal Investigator
- Mary Spellman, MDCastle Creek Pharmaceuticals
- Intervention
- diacerein 1% ointment(drug)
- Enrollment
- 54 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2017 – 2018
Study locations (22)
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Stanford University, Palo Alto, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Northwestern University, Chicago, Illinois, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- University of Missouri Healthcare, Columbia, Missouri, United States
- Stony Brook University Medical Center, Stony Brook, New York, United States
- University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Medical University of South Carolina (MUSC), Charleston, South Carolina, United States
- Children's Hospital of San Antonio ; Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
- Premier Specialists Pty Ltd; The Church, Kogarah, New South Wales, Australia
- EB House Austria, Salzburg, Austria
- Hopital Saint Louis, Paris, Cedex, France
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03154333 on ClinicalTrials.govOther trials for Epidermolysis bullosa simplex
Additional recruiting or active studies for the same condition.